Related Experiment Video
Updated: Feb 22, 2026

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
Association between polymorphisms in microRNA target sites and survival in early-stage non-small cell lung cancer
Seung Soo Yoo1, Mi Jeong Hong2, Jang Hyuck Lee3
1Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
Abstract:
A high-throughput mapping method of RNA-RNA interactions by crosslinking, ligation, and sequencing of hybrids (CLASH) can not only provide information about canonical but also non-canonical interactions. We evaluated the associations between variants in microRNA target sites using CLASH data and survival outcomes of 782 early-stage non-small cell lung cancer (NSCLC) patients who underwent curative surgical resection. Among the 100 variants studied, two variants showed significant association with survival outcomes. The POLR2A rs2071504 C > T variant was associated with poor overall and disease-free survival under a dominant model (hazard ratio [HR] 1.42, 95% confidence interval [CI] 1.08-1.88; P = 0.01 and HR 1.34, 95% CI 1.08-1.67; P = 0.01, respectively). Patients carrying the NR2F6 rs2288539 TT genotype showed significantly better overall survival than those with the NR2F6 rs2288539 CC or CT genotypes (HR 0.13, 95% CI 0.02-0.90; P = 0.04). These findings suggest that POLR2A rs2071504 C > T and NR2F6 rs2288539 C > T can influence prognosis in early-stage NSCLC patients.
Insights
Two genetic variants, POLR2A rs2071504 and NR2F6 rs2288539, are linked to survival in early-stage non-small cell lung cancer (NSCLC) patients. These findings may help predict patient prognosis after surgical resection.
Area of Science:
- Genomics
- Molecular Biology
- Oncology
Background:
- MicroRNA (miRNA) target site variants can influence gene regulation and disease outcomes.
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, necessitating improved prognostic markers.
- Understanding genetic associations with survival is crucial for personalized medicine in NSCLC.
Purpose of the Study:
- To investigate the association between variants in miRNA target sites and survival outcomes in early-stage NSCLC patients.
- To identify specific genetic markers that can predict prognosis in NSCLC.
- To leverage high-throughput RNA-RNA interaction data for clinical relevance.
Main Methods:
- Utilized crosslinking, ligation, and sequencing of hybrids (CLASH) data to identify RNA-RNA interactions.
- Analyzed associations between 100 pre-selected variants in miRNA target sites and survival data from 782 early-stage NSCLC patients.
- Employed statistical models to evaluate the impact of variants on overall survival and disease-free survival.
Main Results:
- The POLR2A rs2071504 C > T variant was significantly associated with poorer overall and disease-free survival (HR=1.42, P=0.01; HR=1.34, P=0.01).
- Patients with the NR2F6 rs2288539 TT genotype exhibited significantly better overall survival compared to CC or CT genotypes (HR=0.13, P=0.04).
- Two specific variants, POLR2A rs2071504 and NR2F6 rs2288539, demonstrated a significant impact on NSCLC patient prognosis.
Conclusions:
- POLR2A rs2071504 C > T and NR2F6 rs2288539 C > T variants are potential prognostic biomarkers for early-stage NSCLC.
- These genetic variants may influence patient outcomes following curative surgical resection.
- Further research can explore the functional mechanisms underlying these associations for therapeutic targeting.
Related Concept Videos
MicroRNAs
MicroRNAs
lncRNA - Long Non-coding RNAs

